Dipal Doshi Biography and Net Worth

Dipal has been Chief Executive Officer of Entrada Therapeutics and a Member of the Board of Directors since joining Entrada in 2017 as its first full-time employee shortly after the Company was founded and funded with seed capital. He previously served as President and Chief Executive Officer from 2017 to 2024.

Dipal has led many critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning, and finance. Prior to joining Entrada, Dipal was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior level positions at a healthcare private equity fund and Catalent. Earlier in his career, Dipal worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company.

Dipal holds an MBA from The Wharton School of the University of Pennsylvania and a BA from Rutgers University. He serves on the Board of Directors of Azenta Life Sciences (NASDAQ: AZTA), a leading provider of life sciences solutions and āshibio, a privately held, clinical-stage biotechnology company. He is also a Fellow of the Aspen Institute and serves on the Board of Advisors of Life Science Cares Boston.

What is Dipal Doshi's net worth?: The estimated net worth of Dipal Doshi is at least $3.40 million as of July 15th, 2024. Doshi owns 334,475 shares of Entrada Therapeutics stock worth more than $3,398,266 as of December 4th. This net worth estimate does not reflect any other assets that Doshi may own. Additionally, Doshi receives a salary of $968,210.00 as CEO at Entrada Therapeutics. Learn More about Dipal Doshi's net worth.
How old is Dipal Doshi?: Doshi is currently 48 years old. There are 3 older executives and no younger executives at Entrada Therapeutics. Learn More on Dipal Doshi's age.
What is Dipal Doshi's salary?: As the CEO of Entrada Therapeutics, Inc., Doshi earns $968,210.00 per year. Learn More on Dipal Doshi's salary.
How do I contact Dipal Doshi?: The corporate mailing address for Doshi and other Entrada Therapeutics executives is , , . Entrada Therapeutics can also be reached via phone at 857-520-9158 and via email at [email protected]. Learn More on Dipal Doshi's contact information.
Has Dipal Doshi been buying or selling shares of Entrada Therapeutics?: Dipal Doshi has not been actively trading shares of Entrada Therapeutics during the past quarter. Most recently, Dipal Doshi sold 1,600 shares of the business's stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.81, for a transaction totalling $28,496.00. Following the completion of the sale, the chief executive officer now directly owns 334,475 shares of the company's stock, valued at $5,956,999.75. Learn More on Dipal Doshi's trading history.
Who are Entrada Therapeutics' active insiders?: Entrada Therapeutics' insider roster includes John Crowley (Director), Dipal Doshi (CEO), Nathan Dowden (President and Chief Operating Officer), Kush Parmar (Director), Natarajan Sethuraman (Insider), and Kory Wentworth (CFO). Learn More on Entrada Therapeutics' active insiders.
Are insiders buying or selling shares of Entrada Therapeutics?: In the last twelve months, Entrada Therapeutics insiders bought shares 3 times. They purchased a total of 178,044 shares worth more than $1,352,567.90. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 685,845 shares worth more than $5,867,281.75. The most recent insider tranaction occured on November, 21st when CFO Kory James Wentworth sold 8,910 shares worth more than $88,921.80. Insiders at Entrada Therapeutics own 8.1% of the company. Learn More about insider trades at Entrada Therapeutics.
Information on this page was last updated on 11/21/2025.

Dipal Doshi Insider Trading History at Entrada Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/15/2024	Sell	1,600	$17.81	$28,496.00	334,475
7/12/2024	Sell	300	$18.00	$5,400.00	336,075
6/13/2024	Sell	1,000	$16.17	$16,170.00	336,375
5/16/2024	Sell	1,800	$15.00	$27,000.00	338,575
2/15/2024	Sell	1,000	$15.00	$15,000.00	243,279
1/16/2024	Sell	1,000	$15.99	$15,990.00	244,279
12/20/2023	Sell	1,000	$15.00	$15,000.00	245,279
11/13/2023	Sell	1,000	$16.23	$16,230.00	246,279
10/17/2023	Sell	1,000	$15.00	$15,000.00	247,279
9/13/2023	Sell	1,000	$15.00	$15,000.00	248,279
8/14/2023	Sell	1,000	$15.67	$15,670.00	201,069
4/27/2023	Sell	2,000	$13.71	$27,420.00	202,069
4/17/2023	Sell	2,092	$18.01	$37,676.92	204,069
3/27/2023	Sell	2,000	$14.72	$29,440.00	255,811
1/27/2023	Sell	2,000	$12.00	$24,000.00	163,835
1/9/2023	Sell	2,410	$15.02	$36,198.20	165,835
12/29/2022	Sell	400	$15.01	$6,004.00	168,245
12/27/2022	Sell	9,669	$15.02	$145,228.38	173,166
11/28/2022	Sell	2,000	$13.91	$27,820.00	182,835
10/27/2022	Sell	2,000	$21.66	$43,320.00	184,835
10/24/2022	Sell	2,342	$19.30	$45,200.60	198,896
10/20/2022	Sell	811	$18.01	$14,606.11	204,024
9/28/2022	Sell	3,085	$15.23	$46,984.55	204,835
9/26/2022	Sell	3,083	$15.32	$47,231.56	212,339
9/23/2022	Sell	1,023	$15.07	$15,416.61	215,422
9/21/2022	Sell	3,402	$15.12	$51,438.24	216,445
9/15/2022	Sell	200	$15.04	$3,008.00	219,847
9/8/2022	Sell	1,100	$15.16	$16,676.00	220,735
8/31/2022	Sell	171	$12.00	$2,052.00	206,710
8/29/2022	Sell	1,639	$12.88	$21,110.32	207,071
7/27/2022	Sell	2,000	$12.00	$24,000.00	208,710
6/27/2022	Sell	4,000	$12.00	$48,000.00	210,710

Dipal Doshi Buying and Selling Activity at Entrada Therapeutics

Entrada Therapeutics Company Overview

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $10.16

$9.52

$10.38

50 Day Range

MA: $7.48

$5.80

$10.26

2 Week Range

Now: $10.16

$4.93

$21.79

Volume

123,914 shs

Average Volume

286,123 shs

Market Capitalization

$388.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Dipal Doshi Biography and Net Worth

What is Dipal Doshi's net worth?

How old is Dipal Doshi?

What is Dipal Doshi's salary?

How do I contact Dipal Doshi?

Has Dipal Doshi been buying or selling shares of Entrada Therapeutics?

Who are Entrada Therapeutics' active insiders?

Are insiders buying or selling shares of Entrada Therapeutics?

Dipal Doshi Insider Trading History at Entrada Therapeutics

Dipal Doshi Buying and Selling Activity at Entrada Therapeutics

Entrada Therapeutics Company Overview

Today's Range

50 Day Range

2 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta